PD-1 inhibitors induced bullous lichen planus-like reactions: A rare presentation and report of three cases

Melanoma Research

Volumn 26, Issue 4, 2016, Pages 421-424

  Wakade, Deepal V ^a,b   Carlos, Giuliana ^a,b   Hwang, Shelley J E ^a,b   Chou, Shaun ^a   Hui, Rina ^a,b   Fernandez Peñas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

acitretin; bullous lichen planus; PD 1

Indexed keywords

AZITHROMYCIN; BETAMETHASONE DIPROPIONATE; CARBOPLATIN; DABRAFENIB; ETRETIN; FIBRINOGEN; GEMCITABINE; HYDROCORTISONE; IMMUNOGLOBULIN M; METOPROLOL; PEMBROLIZUMAB; PIPERACILLIN PLUS TAZOBACTAM; TRAMETINIB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BULLOUS LICHEN PLANUS LIKE REACTION; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION IMPROVEMENT; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOFLUORESCENCE TEST; MALE; MEDICAL HISTORY; METASTATIC MELANOMA; MIDDLE AGED; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PRURITUS; RESPIRATORY FAILURE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; LICHEN PLANUS; MELANOMA; PATHOLOGY; SKIN TUMOR;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; LICHEN PLANUS; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84964789051     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000263     Document Type: Article

References (12)

1. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004; 64:1140-1145.
2. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 2015; 6:3479-3492.
3. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144.
4. Martin-Liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf 2015; 14:957-964.
5. Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016; 74:455.e1-461.e1.
6. Huang C, Chen S, Liu Z, Tao J, Wang C, Zhou Y. Familial bullous lichen planus (FBLP): pedigree analysis and clinical characteristics. J Cutan Med Surg 2005; 9:217-222.
7. Gange RW, Jones EW. Bullous lichen planus caused by labetalol. Br Med J 1978; 1:816-817.
8. Gawkrodger DJ, Stavropoulos PG, McLaren KM, Buxton PK. Bullous lichen planus and lichen planus pemphigoides-clinico-pathological comparisons. Clin Exp Dermatol 1989; 14:150-153.
9. Handa S, Kanwar AJ. Bullous lichen planus. Pediatr Dermatol 1993; 10:393-394.
10. Lage D, Juliano PB, Metze K, de Souza EM, Cintra ML. Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study. Int J Dermatol 2012; 51:1199-1205.
11. Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA, et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 2006; 142:166-172.
12. van Tuyll van Serooskerken AM, van Marion AM, de Zwart-Storm E, Frank J, Poblete-Gutiérrez P. Lichen planus with bullous manifestation on the lip. Int J Dermatol 2007; 46 (Suppl 3):S25-S26.